PEGylated Drugs Market Size, Industry Analysis Report,
Regional Outlook Application Development Potential &
Forecast, 2017 – 2024: Global Market Insights Inc.
Pegylated Drugs Market can be used to treat chronic disorders like cancer. Cancer is of
the leading cause of death and its prevalence is rising continuously. Binding of PEG with
drugs facilitates its entry into the tumor cell and to give better therapeutic results. The
demand for these drugs is high as it offers different advantages such as reduced
degradation by metabolic enzymes, elimination of immunogenicity and increased
residence in blood. It also enhances the solubility of drugs and reduces effects of
proteolytic enzymes, thus improves the bioavailability.
PEGylation refers to change in structure of protein by linking one or more polyethylene
glycol (PEG) chains. It is easily soluble in organic and aqueous solutions and is non-toxic
in nature. The chain binds to the drugs covalently and make it sterically stable. The
polymer thus formed is non-toxic, non-antigenic, non-immunogenic, and highly water
soluble. It further increases half-life of the drug and reduces dose frequency by
preventing renal excretion of drugs.
Increasing protein stability and circulating half-life, and increased R&D spending are
some other impact rendering factors for industry. However, adverse drug reactions
associated can impede market growth during forecast period. Attachment of PEG with
drugs however, comes with certain limitations. In some cases, intravenous
administration resulted in hypersensitivity reactions and blood clots. In other cases, it
resulted in antibody production in body and has also shown hypersensitivity reactions
when administered with laxatives.
PEGylation products consists of different reagents including linkers, cross-linkers, and
labels. Different reagents include AMINE, CARBOXYL, and CARBOXYL PEGylation. Drugs
currently being used in the treatment of cancer, chronic kidney diseases, hepatitis,
multiple sclerosis, hemophilia, and gastrointestinal disorders. Mircera, an
erythropoiesis stimulating agent is approved by FDA for treatment of anemia associated
with chronic renal failure. PEG-INTRON and PEGASYS are other FDA approved products
for treatment of hepatitis C.
1 | Page